Intra-Cellular Therapies Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, is proceeding with Phase 3 development of ITI-007 for the treatment of depressive episodes associated with bipolar disorder. The Phase 3 program in bipolar depression consists of two multicenter, randomized, double blind, placebo controlled clinical trials. The first Phase 3 study will evaluate ITI-007 as a monotherapy and the second Phase 3 study w...